Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

April 11, 2023

Overcoming the Shared Effect Modifier Assumption with Network Meta-Interpolation

Commonly used methods to handle the complexities of effect modification in indirect treatment comparisons (ITCs) often...

Read article

August 10, 2021

CLRPerm: Cytel Scientists and Collaborators Propose a New Method for Meta-analysis for Rare Events

A few weeks ago I wrote about new research conducted by Cytel statisticians, on the challenge of conducting...

Read article

February 9, 2021

New Meta-Analysis in JAMA Uses Novel Quantitative Techniques to Demonstrate Baseline Characteristics Informing Response to Common Therapy for Kidney Cancer

Recent years have witnessed improving survival outcomes for those struggling with a range of common kidney cancers....

Read article

July 21, 2020

Head to Head Comparisons Using Real World Data

Cytel is conducting a webinar series that focuses on target trial emulation and causal inference approaches using real...

Read article

June 23, 2020

Design and Data Source Considerations from Pilot Investigations in CVD

Supposing two treatments, A and B, need to be compared that have not been compared through a clinical trial. In the...

Read article

Therapeutics Development Team

Software

Innovative Trial Design

RWE

HEOR

Biometrics Implementation

Functional Service Provision

CDI

Events

Newsroom

Resources

Perspectives on Enquiry & Evidence

Aligning Clinical Trial Design with Investment Priorities

Overcoming the Shared Effect Modifier Assumption with Network Meta-Interpolation

CLRPerm: Cytel Scientists and Collaborators Propose a New Method for Meta-analysis for Rare Events

New Meta-Analysis in JAMA Uses Novel Quantitative Techniques to Demonstrate Baseline Characteristics Informing Response to Common Therapy for Kidney Cancer

Head to Head Comparisons Using Real World Data

Design and Data Source Considerations from Pilot Investigations in CVD

Subscribe to our weekly newsletter

Subscribe to our weekly newsletter